Cytena secures €3M in funding to advance its single-cell technology

By Nikita Chaurasia  Date: 2019-03-27

Cytena secures €3M in funding to advance its single-cell technology
  • The capital will help to broaden the sales activities of Cytena and capitalize on new applications
  • Single-cells are used in the development of biopharmaceuticals and in stem cell and cancer research

Reports confirm that High-Tech Grunderfonds (HTGF) and two private investors are going to invest another 3 million euros in Cytena GmbH. This capital will be used in developing Cytena’s single-cell printer lab technology, broaden its sales activities and promptly tap into the capabilities of new applications.

Apparently, the two private investors and High-Tech Grunderfonds (HTGF) have confidence in the significance of isolation of single-cell for the development of biopharmaceuticals as well as for genetic analysis in diagnostics and research.

Benjamin Steimle, CFO of Cytena stated that the new capital would help to understand better and serve the customer’s requirements as well as help to increase the market share of the company.

Cytena mentioned that along with way, important milestones achieved include a collaboration in sales with a vital American company and addition of x.sight devices.

In recent years, the analysis of individual biological cells has gained its importance rapidly. These single-cells are used in the development of latest drugs called biopharmaceuticals and also in stem cell and cancer research, the firm said.

Cytena’s single cell printers comprise of laboratory devices for sorting and managing individual viable cells. These instruments are considered as one of the innovative platforms for life science and offer long-term contribution towards the manufacturing and development of new drugs.

According to HTGF Investment Manager, Dr. Lena Krzyzak, investment in the Series A round helps the company to continues its successful growth in start-up financing. Dr. Krzyzak said with the company is greatly confident in its management team’s ability to expand the market and product development.

For the uninitiated, Cytena is a well-known start-up in life sciences which was founded in 2014 at the University of Freiburg, by spinning off from the Institute for Microsystems Technology (IMTEK). The Cytena team has developed the technology called the single-cell printer which enables the isolation of single cells in a gentle, sterile and documented process.

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

1health to offer two types of COVID-19 testing kits to SkyWest Airlines

1health to offer two types of COVID-19 testing kits to SkyWest Airlines

By Nikita Chaurasia

Leading Testing as a Service (TaaS) provider, 1health, recently announced that it has partnered with SkyWest Airlines, a SkyWest Inc. subsidiary, to provide two types of COVID-19 tests to the airline’s personnel. Mehdi Maghsoodnia, CEO at 1hea...

FBI to remove backdoors from hacked Microsoft Exchange email servers

FBI to remove backdoors from hacked Microsoft Exchange email servers

By Nikita Chaurasia

Following the recent cyber-attack in the US, a court in Houston has reportedly authorized a new FBI operation to copy and eliminate backdoors from large number of Microsoft Exchange email servers across the country. During this hacking event, the hac...

France might ban short domestic flights to reduce its carbon footprint

France might ban short domestic flights to reduce its carbon footprint

By Nikita Chaurasia

French lawmakers recently came to a unanimous decision to ban domestic flights for distances that can be covered by train in over two-and-a-half- hours. The country aims to impose these restrictions in an effort to reduce carbon emissions, even as th...

Kavak secures USD 485 million in funding, eyes Latin America expansion

Kavak secures USD 485 million in funding, eyes Latin America expansion

By Nikita Chaurasia

Kavak, a Mexico-based used-car platform, has reportedly reached a valuation of USD 4 billion after securing USD 485 million during a new funding round. This makes it the fastest-growing as well as the most valued company in Latin America. The latest...

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

By Nikita Chaurasia

Indian pharmaceutical company Zydus Cadila is reportedly seeking approval from DCGI (Drug Controller General of India) for its PegIFN (Pegylated Interferon Alpha-2b), a hepatitis C drug, to treat COVID-19 patients, after its third phase of clinical t...